Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney Transplantation: A French Multicenter Cohort.
CMV infection
belatacept
kidney transplantation
opportunistic infections
pneumocystis pneumonia
tacrolimus
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 Oct 2020
28 Oct 2020
Historique:
received:
02
10
2020
revised:
22
10
2020
accepted:
26
10
2020
entrez:
31
10
2020
pubmed:
1
11
2020
medline:
1
11
2020
Statut:
epublish
Résumé
Conversion from calcineurin-inhibitors (CNIs) to belatacept can help kidney-transplant (KT) recipients avoid CNI-related nephrotoxicity. The risk of associated opportunistic infections (OPIs) is ill-defined. We conducted a multicentric cohort study across 15 French KT-centers in a real-life setting. Between 07-2010 and 07-2019, 453 KT recipients were converted from CNI- to belatacept-based therapy at 19 [0.13-431] months post-transplantation. Most patients, i.e., 332 (79.3%), were converted after 6-months post-transplantation. Follow-up time after conversion was 20.1 +/- 13 months. OPIs developed in 42(9.3%) patients after 14 +/- 12 months post-conversion. Eight patients (19%) had two OPI episodes during follow-up. Incidences of CMV DNAemia and CMV disease were significantly higher in patients converted before 6-months post-KT compared to those converted later (i.e., 31.6% vs. 11.5%;
Identifiants
pubmed: 33126667
pii: jcm9113479
doi: 10.3390/jcm9113479
pmc: PMC7693007
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2007 Dec 20;357(25):2562-75
pubmed: 18094377
Transplantation. 2018 Sep;102(9):1545-1552
pubmed: 29570163
Am J Kidney Dis. 2017 May;69(5):587-594
pubmed: 27889299
J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S291-5
pubmed: 17130277
Transpl Int. 2016 Nov;29(11):1184-1195
pubmed: 27514317
Expert Opin Drug Saf. 2015 Oct;14(10):1531-46
pubmed: 26329325
Am J Transplant. 2018 Jul;18(7):1774-1782
pubmed: 29573335
Physiol Res. 2017 May 4;66(2):167-180
pubmed: 27982677
Clin J Am Soc Nephrol. 2011 Feb;6(2):430-9
pubmed: 21051752
Nephrol Dial Transplant. 2020 Feb 1;35(2):336-345
pubmed: 32030416
J Clin Med. 2019 Apr 30;8(5):
pubmed: 31052269
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2213-20
pubmed: 26430088
Transpl Infect Dis. 2017 Jun;19(3):
pubmed: 28273393
Am J Health Syst Pharm. 2013 Nov 15;70(22):1977-83
pubmed: 24173007
Am J Transplant. 2016 Nov;16(11):3192-3201
pubmed: 27130868
N Engl J Med. 2005 Aug 25;353(8):770-81
pubmed: 16120857
J Transplant. 2018 May 2;2018:1968029
pubmed: 29854421
N Engl J Med. 2016 Jun 30;374(26):2600-1
pubmed: 27355541
Am J Transplant. 2018 Jul;18(7):1783-1789
pubmed: 29509295
EBioMedicine. 2018 Aug;34:113-121
pubmed: 30072213
Transplant Direct. 2019 Dec 24;6(1):e517
pubmed: 32047845
N Engl J Med. 2003 Dec 11;349(24):2326-33
pubmed: 14668458
Clin Infect Dis. 2017 Jan 1;64(1):87-91
pubmed: 27682069
Transplantation. 2016 Aug;100(8):1723-31
pubmed: 27306529
Am J Transplant. 2017 Apr;17(4):856-879
pubmed: 28117944
Pediatr Transplant. 2017 Jun;21(4):
pubmed: 28371243
Am J Transplant. 2013 Mar;13(3):656-62
pubmed: 23331474
Iran J Kidney Dis. 2014 May;8(3):231-5
pubmed: 24878947
Am J Transplant. 2010 Mar;10(3):535-46
pubmed: 20415897
J Am Soc Nephrol. 1993 Nov;4(5):1159-71
pubmed: 8305642
Transplantation. 2016 Nov;100(11):2315-2323
pubmed: 27472094
Transplantation. 2018 Jun;102(6):900-931
pubmed: 29596116